A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma

Overview

Journal J Immunother

Specialty Allergy & Immunology

Date 2018 Mar 9

PMID 29517616

Citations 10

Authors

Michael J Robertson

Christopher W Stamatkin

David Pelloso

Jill Weisenbach

Nagendra K Prasad

Ahmad R Safa

Affiliations

Soon will be listed here.

Abstract

Interleukin-18 (IL-18) is an immunostimulatory cytokine that augments antibody-dependent cellular cytotoxicity mediated by human natural killer cells against antibody-coated lymphoma cells in vitro and that has antitumor activity in animal models. Ofatumumab is a CD20 monoclonal antibody with activity against human B-cell lymphomas. A phase I study of recombinant human (rh) IL-18 given with ofatumumab was undertaken in patients with CD20 lymphoma who had undergone high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Cohorts of 3 patients were given intravenous infusions of ofatumumab 1000 mg weekly for 4 weeks with escalating doses of rhIL-18 as a intravenous infusion weekly for 8 consecutive weeks. Nine male patients with CD20 lymphomas were given ofatumumab in combination with rhIL-18 at doses of 3, 10, and 30 μg/kg. No unexpected or dose-limiting toxicities were observed. The mean reduction from predose levels in the number of peripheral blood natural killer cells after the first rhIL-18 infusion was 91%, 96%, and 97% for the 3, 10, and 30 μg/kg cohorts, respectively. Serum concentrations of interferon-γ and chemokines transiently increased following IL-18 dosing. rhIL-18 can be given in biologically active doses by weekly infusions in combination with ofatumumab after peripheral blood stem cell transplantation to patients with lymphoma. A maximum tolerated dose of rhIL-18 plus ofatumumab was not determined. Further studies of rhIL-18 and CD20 monoclonal antibodies in B-cell malignancies are warranted.

Citing Articles

Role of Non-Binding T63 Alteration in IL-18 Binding.

Peeyatu C, Prompat N, Voravuthikunchai S, Roongsawang N, Sangkhathat S, Khongkow P Int J Mol Sci. 2024; 25(23).

PMID: 39684709 PMC: 11641284. DOI: 10.3390/ijms252312992.

Synthetic Cells and Molecules in Cellular Immunotherapy.

Lin H, Li C, Zhang W, Wu B, Wang Y, Wang S Int J Biol Sci. 2024; 20(8):2833-2859.

PMID: 38904025 PMC: 11186374. DOI: 10.7150/ijbs.94346.

Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner.

Hull C, Larcombe-Young D, Mazza R, George M, Davies D, Schurich A Mol Ther. 2024; 32(7):2373-2392.

PMID: 38745414 PMC: 11286818. DOI: 10.1016/j.ymthe.2024.05.013.

Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition.

Lipinski B, Unmuth L, Arras P, Becker S, Bauer C, Toleikis L MAbs. 2023; 15(1):2236265.

PMID: 37469014 PMC: 10361135. DOI: 10.1080/19420862.2023.2236265.

Cancer Immunotherapy Beyond Checkpoint Blockade: State-of-the-Art Review.

Welty N, Gill S JACC CardioOncol. 2023; 4(5):563-578.

PMID: 36636439 PMC: 9830230. DOI: 10.1016/j.jaccao.2022.11.006.

References

Teeling J, Mackus W, Wiegman L, van den Brakel J, Beers S, French R . The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006; 177(1):362-71. DOI: 10.4049/jimmunol.177.1.362. View

Hagenbeek A, Gadeberg O, Johnson P, Moller Pedersen L, Walewski J, Hellmann A . First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008; 111(12):5486-95. DOI: 10.1182/blood-2007-10-117671. View

Robertson M . Role of chemokines in the biology of natural killer cells. J Leukoc Biol. 2002; 71(2):173-83. View

Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17(4):1244. DOI: 10.1200/JCO.1999.17.4.1244. View

Logan T, Robertson M . Interleukins 18 and 21: biology, mechanisms of action, toxicity, and clinical activity. Curr Oncol Rep. 2006; 8(2):114-9. DOI: 10.1007/s11912-006-0046-0. View

Klingemann H, Phillips G . Immunotherapy after bone marrow transplantation. Bone Marrow Transplant. 1991; 8(2):73-81. View

Robertson M, Chang H, Pelloso D, Kaplan M . Impaired interferon-gamma production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma. Blood. 2005; 106(3):963-70. PMC: 1895167. DOI: 10.1182/blood-2005-01-0201. View

Cheson B . Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol. 2010; 28(21):3525-30. DOI: 10.1200/JCO.2010.27.9836. View

Robertson M, Abonour R, Hromas R, Nelson R, Fineberg N, Cornetta K . Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2005; 46(10):1477-87. DOI: 10.1080/10428190500158466. View

10.

Lupov I, Voiles L, Han L, Schwartz A, De La Rosa M, Oza K . Acquired STAT4 deficiency as a consequence of cancer chemotherapy. Blood. 2011; 118(23):6097-106. PMC: 3234667. DOI: 10.1182/blood-2011-03-341867. View

11.

Yuen A, Rosenberg S, Hoppe R, Halpern J, Horning S . Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood. 1997; 89(3):814-22. View

12.

Robertson M, Soiffer R, Wolf S, Manley T, Donahue C, Young D . Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med. 1992; 175(3):779-88. PMC: 2119162. DOI: 10.1084/jem.175.3.779. View

13.

Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O . Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol. 2002; 20(2):467-75. DOI: 10.1200/JCO.2002.20.2.467. View

14.

TANNENBAUM C, Tubbs R, Armstrong D, Finke J, Bukowski R, Hamilton T . The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol. 1998; 161(2):927-32. View

15.

Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333(23):1540-5. DOI: 10.1056/NEJM199512073332305. View

16.

Gluck W, Hurst D, Yuen A, Levine A, Dayton M, Gockerman J . Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res. 2004; 10(7):2253-64. DOI: 10.1158/1078-0432.ccr-1087-3. View

17.

Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I . Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity. Clin Cancer Res. 2016; 22(10):2329-34. DOI: 10.1158/1078-0432.CCR-16-0224. View

18.

Barth M, Mavis C, Czuczman M, Hernandez-Ilizaliturri F . Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma. Clin Cancer Res. 2015; 21(19):4391-7. PMC: 5685505. DOI: 10.1158/1078-0432.CCR-15-0056. View

19.

Trotta R, Dal Col J, Yu J, Ciarlariello D, Thomas B, Zhang X . TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol. 2008; 181(6):3784-92. PMC: 2924753. DOI: 10.4049/jimmunol.181.6.3784. View

20.

Ansell S, Witzig T, Kurtin P, Sloan J, Jelinek D, Howell K . Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 2002; 99(1):67-74. DOI: 10.1182/blood.v99.1.67. View